The following is an excerpt.
Myriad argues that they should be allowed to patent the gene because they were the first ones to remove it from the rest of the human genome. These removed or “isolated” genes give the patent-holder exclusive rights to all clinical testing and research on the genes. As a result, Myriad has forced a monopoly on gene research for BRCA1 and BRCA2.
This patent (and subsequent monopoly) is dangerous as it prohibits research on these genes by other companies and laboratories. And since these genes have been connected to hereditary breast cancer, it is now less likely that a gene-based cure will be found.
View the original article here: Myriad Genetics Patent Would Harm Society
